Mediar Therapeutics

biotech

New perspective. Novel targets. Clinical trials. The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in organ systems. By deactivating the myofibroblast, we hope to slow fibrosis and possibly reverse it.  Mediar is running clinical studies in fibrosing diseases to bring new potential options for patients and their caregivers. Fearlessly […]